Savara (SVRA) Free Cash Flow (2010 - 2026)
Savara (SVRA) reported Free Cash Flow of -$33.1 million for Q1 2026, down 21.56% year-over-year from -$42.1 million in Q1 2025, and down 31.9% on a QoQ basis from -$25.1 million in Q4 2025.
Savara (SVRA) has 17 years of Free Cash Flow data on file, last reported at -$33.1 million in Q1 2026.
- Quarterly Free Cash Flow fell 21.56% year-over-year to -$33.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$106.9 million (down 11.78% YoY) and the FY2025 annual result came in at -$101.1 million, down 13.41% from the prior year.
- Free Cash Flow slipped to -$33.1 million in Q1 2026 per SVRA's latest filing, from -$25.1 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.2 million in Q3 2022 and bottomed at -$33.1 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$20.7 million (2024), against an average of -$18.2 million.
- The widest annual swing landed in 2022, when Free Cash Flow climbed 23.6%; it then slumped 114.5% in 2024.
- Tracing SVRA's Free Cash Flow over 5 years: stood at -$8.7 million in 2022, then tumbled by 80.64% to -$15.6 million in 2023, then plunged by 48.92% to -$23.3 million in 2024, then declined by 7.68% to -$25.1 million in 2025, then plunged by 31.9% to -$33.1 million in 2026.
- Per Business Quant, the three latest SVRA Free Cash Flow figures stand at -$33.1 million (Q1 2026), -$25.1 million (Q4 2025), and -$22.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -33.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.05 Mn |
| Mar 31, 2026 | -33.05 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.28 Mn |
| Jun 30, 2025 | -26.28 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Dec 31, 2024 | -23.27 Mn |
| Dec 31, 2024 | -23.27 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Jun 30, 2024 | -22.52 Mn |
| Jun 30, 2024 | -22.52 Mn |
| Mar 31, 2024 | -20.65 Mn |
| Mar 31, 2024 | -20.65 Mn |
| Dec 31, 2023 | -15.63 Mn |
| Dec 31, 2023 | -15.63 Mn |
| Sep 30, 2023 | -13.20 Mn |
| Sep 30, 2023 | -13.20 Mn |
| Jun 30, 2023 | -10.50 Mn |
| Jun 30, 2023 | -10.50 Mn |
| Mar 31, 2023 | -12.03 Mn |
| Mar 31, 2023 | -12.03 Mn |
| Dec 31, 2022 | -8.65 Mn |
| Dec 31, 2022 | -8.65 Mn |
| Sep 30, 2022 | -8.17 Mn |
| Sep 30, 2022 | -8.17 Mn |
| Jun 30, 2022 | -9.32 Mn |
| Jun 30, 2022 | -9.32 Mn |
| Mar 31, 2022 | -8.43 Mn |
| Mar 31, 2022 | -8.43 Mn |
| Dec 31, 2021 | -9.40 Mn |
| Dec 31, 2021 | -9.40 Mn |
| Sep 30, 2021 | -8.94 Mn |
| Sep 30, 2021 | -8.94 Mn |
| Jun 30, 2021 | -12.19 Mn |
| Jun 30, 2021 | -12.19 Mn |
| Mar 31, 2021 | -9.60 Mn |
| Mar 31, 2021 | -9.60 Mn |
| Dec 31, 2020 | -12.31 Mn |
| Dec 31, 2020 | -12.31 Mn |
| Sep 30, 2020 | -6.72 Mn |
| Sep 30, 2020 | -6.72 Mn |
| Jun 30, 2020 | -7.77 Mn |
| Jun 30, 2020 | -7.77 Mn |
| Mar 31, 2020 | -13.08 Mn |
| Mar 31, 2020 | -13.08 Mn |
| Dec 31, 2019 | -9.96 Mn |
| Dec 31, 2019 | -9.96 Mn |
| Sep 30, 2019 | -11.42 Mn |
| Sep 30, 2019 | -11.42 Mn |
| Jun 30, 2019 | -12.94 Mn |
| Jun 30, 2019 | -12.94 Mn |
| Mar 31, 2019 | -10.96 Mn |
| Mar 31, 2019 | -10.96 Mn |
| Dec 31, 2018 | -10.55 Mn |
| Dec 31, 2018 | -10.55 Mn |
| Sep 30, 2018 | -8.78 Mn |
| Sep 30, 2018 | -8.78 Mn |
| Jun 30, 2018 | -10.40 Mn |
| Jun 30, 2018 | -10.40 Mn |
| Mar 31, 2018 | -9.69 Mn |
| Mar 31, 2018 | -9.69 Mn |
| Dec 31, 2017 | -9.90 Mn |
| Dec 31, 2017 | -9.90 Mn |
| Sep 30, 2017 | -8.25 Mn |
| Sep 30, 2017 | -8.25 Mn |
| Jun 30, 2017 | -7.67 Mn |
| Jun 30, 2017 | -7.67 Mn |
| Mar 31, 2017 | -2.90 Mn |
| Mar 31, 2017 | -2.90 Mn |
| Dec 31, 2016 | -2.19 Mn |
| Dec 31, 2016 | -2.19 Mn |
| Sep 30, 2016 | -2.87 Mn |
| Sep 30, 2016 | -2.87 Mn |
| Jun 30, 2016 | 8.01 Mn |
| Jun 30, 2016 | 8.01 Mn |
| Mar 31, 2016 | -11.33 Mn |
| Mar 31, 2016 | -11.33 Mn |
| Dec 31, 2015 | 19.31 Mn |
| Dec 31, 2015 | 19.31 Mn |
| Sep 30, 2015 | -8.28 Mn |
| Sep 30, 2015 | -8.28 Mn |
| Jun 30, 2015 | -8.55 Mn |
| Jun 30, 2015 | -8.55 Mn |
| Mar 31, 2015 | -7.42 Mn |
| Mar 31, 2015 | -7.42 Mn |
| Dec 31, 2014 | -6.03 Mn |
| Dec 31, 2014 | -6.03 Mn |
| Sep 30, 2014 | -5.40 Mn |
| Sep 30, 2014 | -5.40 Mn |
| Jun 30, 2014 | -7.09 Mn |
| Jun 30, 2014 | -7.09 Mn |
| Mar 31, 2014 | -6.28 Mn |
| Mar 31, 2014 | -6.28 Mn |
| Dec 31, 2013 | -4.86 Mn |
| Dec 31, 2013 | -4.86 Mn |
| Sep 30, 2013 | -3.80 Mn |
| Sep 30, 2013 | -3.80 Mn |
| Jun 30, 2013 | -4.68 Mn |
| Jun 30, 2013 | -4.68 Mn |
| Mar 31, 2013 | -4.49 Mn |
| Mar 31, 2013 | -4.49 Mn |
| Dec 31, 2012 | -3.40 Mn |
| Dec 31, 2012 | -3.40 Mn |
| Sep 30, 2012 | -3.17 Mn |
| Sep 30, 2012 | -3.17 Mn |
| Jun 30, 2012 | -2.96 Mn |
| Jun 30, 2012 | -2.96 Mn |
| Mar 31, 2012 | -4.65 Mn |
| Mar 31, 2012 | -4.65 Mn |
| Dec 31, 2011 | -3.22 Mn |
| Dec 31, 2011 | -3.22 Mn |
| Sep 30, 2011 | -3.66 Mn |
| Sep 30, 2011 | -3.66 Mn |
| Jun 30, 2011 | -4.60 Mn |
| Jun 30, 2011 | -4.60 Mn |
| Mar 31, 2011 | -2.40 Mn |
| Mar 31, 2011 | -2.40 Mn |
| Dec 31, 2010 | -1.36 Mn |
| Dec 31, 2010 | -1.36 Mn |
| Sep 30, 2010 | -1.83 Mn |
| Sep 30, 2010 | -1.83 Mn |